Editas Medicine Inc

NASDAQ:EDIT   3:59:54 PM EDT
37.94
-0.27 (-0.71%)
Products, Regulatory

Editas Medicine Inc Announces Positive Initial Clinical Data From Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Published: 09/29/2021 13:40 GMT
Editas Medicine Inc (EDIT) - Editas Medicine Announces Positive Initial Clinical Data From Ongoing Phase 1/2 Brilliance Clinical Trial of Edit-101 for Lca10.
Editas Medicine Inc - No Serious Adverse Events Or Dose-limiting Toxicities Observed to Date.
Editas Medicine Inc - Efficacy Signals in Mid-dose Cohort Provide Initial Support for Clinical Benefits.
Editas Medicine Inc - Treatment in Adult High-dose Cohort Continues and Pediatric Mid-dose Cohort Commencing.